Publication | Closed Access

Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent

Tumor BiologyOncogenic AgentMedicineIsogenic Cell LinesPathologyCancer GenomicsMek Inhibitor ActivityMolecular DiagnosticsPi3kca Mutation StatusOncologyCell BiologyTumor MicroenvironmentCancer Research